|
|
Press Releases
|
|
= Add Release to Briefcase |
| All Releases |
 |
Amicus Therapeutics Announces First Quarter 2008 Results Release Date
May 8, 2008
|
8.3 KB
|
| |
CRANBURY, N.J., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus (Nasdaq: FOLD) will announce first quarter 2008 financial results after the regular close of markets on Tuesday, May 13, 2008. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.
Interested participants ...
|
|
 |
Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Apr 24, 2008
|
7.6 KB
|
| |
CRANBURY, N.J., April 24 -- Amicus Therapeutics
Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief
Executive Officer, will present a corporate update at the Morgan Stanley
Global Healthcare Unplugged Conference on Wednesday, April 30, 2008, at 2:20
p.m. EDT, at the Ritz-Carlton in Key Biscayne, Florida. The present...
|
|
 |
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Mar 13, 2008
|
10.9 KB
|
| |
CRANBURY, N.J., March 13, 2008 /PRNewswire via COMTEX News Network/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present positive results from an ex vivo response study and three Phase 1...
|
|
 |
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Mar 13, 2008
|
11.2 KB
|
| |
CRANBURY, N.J., March 13, 2008 /PRNewswire via COMTEX News Network/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present positive results from a Phase 2 clinical study of Plicera(TM) (is...
|
|
 |
Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
Feb 7, 2008
|
9.3 KB
|
| |
CRANBURY, N.J., Feb 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at BIO CEO & Investor Conference 2008 in New York, NY on Monday, February 11, 2008 at 12:30 pm (Eastern Standard Time) at...
|
|
 |
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Feb 1, 2008
|
9.3 KB
|
| |
CRANBURY, N.J., Feb 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York, NY on Thursday, Februa...
|
|
 |
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Jan 29, 2008
|
25.2 KB
|
| |
CRANBURY, N.J., Jan 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally- active pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the fourth quarter and full year of 2007. On a reported...
|
|
 |
Amicus Therapeutics Announces Positive Interim Results From Phase 2 Clinical Trial of Plicera for Gaucher Disease
Jan 7, 2008
|
11.5 KB
|
| |
CRANBURY, N.J., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today positive interim results from a Phase 2 clinical trial of Plicera
|
|
|
 |
Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
Jan 2, 2008
|
9.3 KB
|
| |
CRANBURY, N.J., Jan 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the 26th Annual JPMorgan Healthcare Conference in San Francisco, CA on Monday, January 7, 2008 at 11:30 am (Pacific St...
|
|
 |
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Dec 19, 2007
|
14.5 KB
|
| |
CRANBURY, N.J., Dec 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today positive results from its recently completed Phase 2 clinical trial...
|
|
 |
Amicus Therapeutics to Host R&D Day
Nov 27, 2007
|
9.3 KB
|
| |
CRANBURY, N.J., Nov 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it will host an "R&D Day" meeting on December 19, 2007 from 4:30 to 7:00 PM at the Four Seasons Hotel in New York City. The presentation will include a summary of the results of the Phase 2 clinical trials performed...
|
|
 |
Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
Nov 20, 2007
|
9.3 KB
|
| |
CRANBURY, N.J., Nov 20, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Lazard Capital Markets Fourth Annual Healthcare Conference in New York City on Tuesday, November 27th at 11:30 am ET at ...
|
|
 |
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Nov 8, 2007
|
13.0 KB
|
| |
CRANBURY, N.J., Nov 08, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics, Inc. (Nasdaq: FOLD) announced today that it has entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a subsidiary of Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop Amicus' three lead pharmacological chap...
|
|
 |
Amicus Therapeutics Announces Third Quarter 2007 Financial Results
Oct 31, 2007
|
16.5 KB
|
| |
CRANBURY, N.J., Oct 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the third quarter of 2007. On a reported basis calculate...
|
|
 |
Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Oct 23, 2007
|
47.7 KB
|
| |
CRANBURY, N.J., October 23, 2007 -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today positive results from two recently completed Phase 1 clinical studies of AT2220 (1-deoxynojirimycin HCl) f...
|
|
 |
Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
Sep 18, 2007
|
8.4 KB
|
| |
CRANBURY, N.J., Sept 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it plans to present the results of Phase 1 studies of AT2220 (1-deoxynojirimycin HCl) for Pompe Disease at the American Society of Human Genetics (ASHG) Annual Meeting on October 23-27 in San Diego, CA. This plan w...
|
|
 |
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
Sep 12, 2007
|
9.3 KB
|
| |
CRANBURY, N.J., Sept 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John Crowley, President and Chief Executive Officer, will present a corporate update at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference in London, United Kingdom on Tuesday, September 18t...
|
|
 |
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Aug 7, 2007
|
12.7 KB
|
| |
Cranbury, NJ, August 2, 2007 - Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the second quarter of 2007. On a reported basis, calculated in accordance with U.S. gene...
|
|
 |
Amicus Therapeutics (FOLD) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell
May 31, 2007
|
9.2 KB
|
| |
ADVISORY, May 31, 2007 (PrimeNewswire via COMTEX News Network) --
What:
John F. Crowley, President and Chief Executive Officer of Amicus
Therapeutics (FOLD), will preside over the closing bell to celebrate
the Company's initial public offering on NASDAQ.
Where:
NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Stud...
|
|
 |
Amicus Therapeutics Announces Pricing of Initial Public Offering of 5,000,000 Shares of Common Stock
May 31, 2007
|
9.2 KB
|
| |
CRANBURY, N.J., May 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today the pricing of its initial public offering (IPO) of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Amicus has granted the underwriters a 30-day option to purchase up to an additional...
|
|
|
|
|